BioTime Appoints Franklin Berger to Board of Directors ALAMEDA, Calif.--(BUSINESS WIRE)

Appoints Franklin Berger to Board of Directors

ALAMEDA, Calif.--(BUSINESS WIRE)--May 14, 2013--BioTime, Inc. (NYSE MKT:

BTX) today announced that Franklin M. Berger, CFA, 63, has been

appointed to its Board of Directors.

"We are pleased to welcome a recognized biotechnology industry expert of

Franklin's caliber to BioTime's Board," said Alfred D. Kingsley,

Chairman of the Board of BioTime. "Franklin adds to our Board a great

deal of experience as a director of biotechnology companies, as an

advisor to biopharma, and as a recognized leader in the analysis and

financing of biotechnology companies. His deep understanding of the

scientific, technological, business, and financial aspects of the

biotechnology sector, coupled with his extensive analytical, financial,

and board experience, will be valuable additions to our Board during an

exciting period of growth for BioTime."

"BioTime's development and acquisition of novel technologies in the stem

cell space over the last few years has established it as a leader in

regenerative medicine," said Mr. Berger. "Regenerative medicine has the

potential to be the next major step forward in biotechnology, and may

lead to significant improvements in the health and quality of life of

patients around the world. I am honored to join the BioTime Board of

Directors as the company moves toward the expansion of its technology

platform and its entry into clinical trials, and look forward to

contributing to the development of these new technologies."

Mr. Berger currently serves as a director of several biotechnology

companies both public and private, and as a consultant to major

biopharmaceutical firms, mid-capitalization biotechnology companies,

specialist asset managers and venture capital firms. In addition to his

board roles, he routinely advises companies regarding business

development, strategic advisory/financings, partnering, and royalty

acquisition. In October 2011, Mr. Berger accepted the position of Senior

Advisor to PDL BioPharma, Inc., a premier biotech royalty company. He

currently serves on the boards of three public biotechnology companies,

Seattle Genetics, Thallion Pharmaceuticals, and Bellus Health, Inc. He

also serves on the board of Five Prime Therapeutics, Inc., a private

biotech company, and he has previously served on the boards of several

other public and private biotechnology companies. Mr. Berger's

distinguished career in the investment industry included roles in

investment management and over twelve years as a leading equity research

analyst covering biotechnology companies, most recently as Managing

Director, U.S. Equity Research, at J.P. Morgan Securities, Inc. from

1998 to 2003. During the course of his career, Mr. Berger was involved

with the issuance of over $12 billion in biotechnology company equity or

equity-linked securities, including Roche's Genentech initial public

offering in 1999, the largest biotechnology financing to date. Mr.

Berger received his BA and MA degrees from Johns Hopkins University in

1971 and 1972, respectively, and received his MBA degree from Harvard

Also, Arnold I. Burns, 83, retired from BioTime's Board of Directors.

Mr. Burns notified the BioTime Board that due to health concerns, he

could no longer continue to productively serve as a director. "Arnie's

advice and counsel will be sorely missed by our Board," said Mr.

Kingsley. "We look forward to consulting with Arnie from time to time in

the future, and wish him well as he focuses on other matters."

BioTime, headquartered in Alameda, California, is a biotechnology

company focused on regenerative medicine and blood plasma volume

expanders. Its broad platform of stem cell technologies is enhanced

through subsidiaries focused on specific fields of application. BioTime

develops and markets research products in the fields of stem cells and

regenerative medicine, including a wide array of proprietary PureStem

cell lines, HyStem hydrogels, culture media, and

differentiation kits. BioTime is developing Renevia (formerly

known as HyStem -Rx), a biocompatible,

implantable hyaluronan and collagen-based matrix for cell delivery in

human clinical applications. BioTime's therapeutic product development

strategy is pursued through subsidiaries that focus on specific organ

systems and related diseases for which there is a high unmet medical

need. BioTime's majority owned subsidiary Cell Cure Neurosciences Ltd.

is developing therapeutic products derived from stem cells for the

treatment of retinal and neural degenerative diseases. BioTime's

subsidiary OrthoCyte Corporation is developing therapeutic applications

of stem cells to treat orthopedic diseases and injuries. Another

subsidiary, OncoCyte Corporation, focuses on the diagnostic and

therapeutic applications of stem cell technology in cancer, including

the diagnostic product PanC-Dx currently being developed for the

detection of cancer in blood samples. ReCyte Therapeutics, Inc. is

developing applications of BioTime's proprietary induced pluripotent

stem cell technology to reverse the developmental aging of human cells

to treat cardiovascular and blood cell diseases. BioTime's subsidiary

LifeMap Sciences, Inc. markets GeneCards , the

leading human gene database, as part of an integrated database suite

that also includes the LifeMap Discovery database of embryonic

development, stem cell research and regenerative medicine, and MalaCards,

the human disease database. LifeMap Sciences also markets BioTime

research products and PanDaTox, an innovative, recently

developed, searchable database that can aid in the discovery of new

antibiotics and biotechnologically beneficial products. Asterias

Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem

cell assets of Geron Corporation, including patents and other

intellectual property, biological materials, reagents and equipment for

the development of new therapeutic products for regenerative medicine.

BioTime's lead product, Hextend , is a blood

plasma volume expander manufactured and distributed in the U.S. by

Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under

exclusive licensing agreements. Additional information about BioTime can

be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results,

future growth in research, technology, clinical development, and

potential opportunities for BioTime and its subsidiaries, along with

other statements about the future expectations, beliefs, goals, plans,

or prospects expressed by management constitute forward-looking